APPLICATION OF THE ESSENTIAL FATTY ACID'S PREPARATION «LIPOSAN-FORTE» AGAINST THE BACKGROUND OF LONG-TERM ADMINISTRATION OF PREDISOLONE IN WHITE RATS
DOI:
https://doi.org/10.35220/2078-8916-2020-38-4-9-16Keywords:
prednisone, glucocorticoids, bone tissue, bone density, polyunsaturated fatty acids, «Liposan-forte»Abstract
The aim. To assess the osteoprotective properties of the essential fatty acid’s preparation "Liposan-forte (vitamin F)" against the background of long-term administration of prednisolone to white rats.
Materials and methods. The experiment was carried out on female white Wistar rats at the age of 4 months for 35 days. Experimental groups: 1 – vivarium diet (n = 7), 2 – fat-free diet (FFD, n = 6), 3 – FFD + prednisolone (n = 6), 4 – FFD + prednisolone + «Liposan-forte» (n = 7). Prednisolone in a daily dose of 5 mg / kg was adminis-tered to rats as a solution through drinking bowls. The drug "Liposan-forte" was used (1 % of the mass of feed) with a ratio of ω-6 and ω-3 polyunsaturated fatty acids (PUFA) 1.15. The density of the femurs, femur distal epiphyses and lumbar vertebrae, the relative contents of organic and mineral components in the bones were de-termined. Changes in bone metabolism were analyzed by the activity of elastase, alkaline and acid phosphatases, and calcium content in the alveolar bone.
Conclusion. Prednisolone caused a decrease of femurs and vertebrae densities by reducing the content of the mineral component and increasing the content of the or-ganic component. Prednisolone predominantly stimulated the resorption of highly mineralized bone tissue and in-hibited the process of calcification of the newly formed bone tissue. These results correlated with biochemical markers of bone metabolism in the alveolar bone. The use of the preparation "Liposan-forte" against the back-ground of the administration of prednisolone contributed to the normalization of bone health indicators. The osteoprotective effect of «Liposan-forte» is associated with its high content of ω-3 PUFAs and vitamin D2.
References
Protective effect of dietary oils containing omega-3 fatty acids against glucocorticoid-induced osteoporosis / A.S. Elbahnasawy, E.R. Valeeva, E.M. El-Sayed [et al.] // J. Nutr. Health. – 2019. – V.52(4). – P. 323–331.
Resolution of vitamin D insufficiency in osteopenic patiens results in rapid recovery of bone mineral density / J.S. Adams, V. Kantorovoch, C. Wu [et al.] // J. Clin. Endocrinol. Metab. – 1999. – V. 84. – P. 2729–2730.
Buxton E.C. Changes in serum receptor activator of nu-clear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone / E.C. Buxton, W. Yao, N.E. Lane // J. Clin. Endocrinol. Metab. – 2004. – 89. – P. 1–34.
Wang T. Pro-inflammatory cytokines: cellular and mo-lecular drug targets for glucocorticoid-induced osteoporosis via osteocyte / T. Wang, X.Yu, C. He // Curr. Drug. Targets. – 2019. – 20(1). – P. 1–15.
Поворознюк В.В. Регуляция эстрогенами ремоде-лирования костной ткани / В.В. Поворознюк, Н.А. Резни-ченко, Э.А. Майлян // Эндокринология. – 2014. – № 1(5). – С.14–18.
Влияние гормонального статуса на развитие остео-пороза и переломов костей у мужчин (Обзор литературы) / О.Б. Ершова, О.С. Синицина, К.Ю. Белова ]и др.] // Мед. со-вет. – 2013. – № 3. – С. 72–75.
Glucocorticoid-induced osteoporosis / L.H. Gregório, P.G.S. Lacativa, A.C.C. Melazzi [et al.] // Arg. Bras. Endocrinol Metab. – 2006. – V. 50. – № 4. – P.793–801.
Поворознюк В.В. Внескелетные эффекты витамина D / В.В. Поворознюк, Н.А. Резниченко, Э.А. Майлян // Біль. Суглоби. Хребет. – 2014. – № 1–2(13–14). – С. 19–25.
Feeding soy protein isolate and oils rich in omega-3 polyunsaturated fatty acids affected mineral balance, but not bone in a rat model of autosomal recessive polycystic kidney disease / K.H. Maditz, B.J. Smith, M. Miller [et al.] // BMC Nephrol. – 2015. – 16(1). – P.13.
Omega-3 fatty acids modulate ATPase involved in du-odenal Ca absorption / M. Haag, O.N. Magada, N. Claassen [et al.] // Prostaglandins Leukoc. Essent. Fatty Acids. – 2003. – 68. – P. 423–429.
Патент на корисну модель № 142656 «Спосіб моде-лювання авітамінозу F» / А.П. Левицький, І.В. Ходаков, В.М. Батіг та ін. // № заявки u 2019 10877. Бюл. № 12 від 25.06.2020.
Липосан-форте (витамин F, препарат ω-3 ПНЖК) / [Левицкий А.П., Ходаков И.В., Лапинская А.П. и др.]– Одесса: ФЛП Таценко С.Ю., 2020. – 16 с.
Ходаков І.В. Спосіб визначення щільності кісток лабораторних тварин / І.В. Ходаков // Досягнення біології та медицини. – 2004. – № 2(4). – С. 38-41.
Экспериментальные методы исследования стиму-ляторов остеогенеза. Методические рекомендации / [Левиц-кий А.П., Макаренко О.А., Деньга О.В. и др.] – Киев: Изда-тельский дом «Авицена», 2005. – С. 16–20.
Левицкий А.П. Методы определения активности эластазы и ее ингибиторов: методические рекомендации / А.П. Левицкий, А.В. Стефанов. – К.: ГФЦ, 2002. – 15 с.
Горячковский А.М. Клиническая биохимия в ла-бораторной диагностике [3-е изд.] / А.М. Горячковский − Одесса: Экология, 2005. – 616 с.
Kruger M.C. Calcium metabolism, osteoporosis and essential fatty acids: a review / M.C. Kruger, D.F. Horrobin // Progress in lipid research. – 1997. – 36(2-3). – P. 131–151.
Leonard F. Modulation of intestinal vitamin D recep-tor availability and calcium ATPase activities by essential fatty acids / F. Leonard, M. Haag, M. Kruger // Prostaglandins, Leucotriens and Essential Fatty Acids. – 2001. – 64(3). – P.147–150.
Valentine R. Omega-3 fatty acids in cellular mem-branes: a unified concept / R. Valentine, D. Valentine // Prog. Lipid Res. – 2004. – 43. – P. 383–402.
The plasma membrane Ca2+-ATPase isoform 4 is local-ized in lipid rafts of cerebellum synaptic plasma membranes / M.R. Sepulveda, M.B. Berrocal-Carrilo, M. Gasset et al. // J. Biol. Chem. – 2006. – 281. – P.447– 453.
A systematic review of omega-3 fatty acids and osteo-porosis / T.S. Orchard, X. Pan, F. Cheek et al. // British J. of Nu-trition. – 2012. – 107. – P. S253–S260.
The effect of omega-3 fatty acid on vitamin D activa-tion in hemodialysis patients: a pilot study / S.M. Lee, Y.K. Son, S.E. Kim [et al.] // Mar. Drugs. – 2015. – 13(2). – P. 741–755.
Poulsen R.C. Long-chain polyunsaturated fatty acids and the regulation of bone metabolism / R.C. Poulsen, P.J. Moughan, C. Kruger // Exp. Biol. Med.(Maywood). – 2007. – 232. – P. 1275–1288.
Роль полиненасыщенных жирных кислот в проте-кании сердечно-соcудистых заболеваний у детей, страдаю-щих ожирением / Ю.Г. Самойлова, О.А. Олейник, Е.В. Са-ган [и др.] // Современные проблемы науки и образования. – 2019. – № 6. – С. 114–128.
Identification of inflammatjry and ptoresolving lipid mediators in bone marrow and their lipidomic profiles with ovariectomy and omega-3 intake / R.C. Poulsen, K.H. Gotlinger, C.N. Serhan et al.// Am. J. Hematol. – 2008. – 83(6). – P. 437–445.
Gyurko R. The role of polyunsaturated ω-3 fatty acid eicosapentaenoic acid-derived resolving E1 (RvE1) in bone preservation / R. Gyurko, T.E. van Dyke // Immunology. – 2014. – 34(4). – P. 347–357.
An endogenous regulator of inflammation, resolving E1, modulates osreoclast differentiation and bone resorption / B.S. Herrera, T. Ohira, L. Gao et al. // Br. J. Pharmacol. – 2008. – 155(8). – P. 1214–1223.
